Oct 26, 2020 / 12:00PM GMT
Operator
Greetings. Welcome to Allakos Lirentelimab Subcutaneous and Prevalence Study Results Conference Call. (Operator Instructions) Please note this conference is being recorded.
I will now turn the conference over to your host, CEO, Robert Alexander. You may begin.
Robert Alexander - Allakos Inc. - CEO & Director
Okay. Well, thank you, and I'd like to thank everybody for joining the call. Alan, can you key ahead one slide. So just a reminder that I will be making forward-looking statements, so please refer to our SEC filings for a description of our risk factors. Agenda.
Okay. So in terms of what we'll go through today, we -- I'll give a brief overview, and then Henrik will show the subcutaneous data, followed by Amol Kamboj, who's going through our prevalence results. And then we'll have 2 key opinion leaders join us to put the prevalence data in a broader context. And then we'll follow-up with Henrik giving an update on the current clinical plans, and then we'll go to Q&A.
Okay. So today's -- I think as everybody knows, today's
Allakos Inc Results From Phase 1 Study Of Subcutaneously Administered Lirentelimab (AK002) Call Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers